169 related articles for article (PubMed ID: 1699659)
1. Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.
Grem JL; Allegra CJ
Cancer Res; 1990 Nov; 50(22):7279-84. PubMed ID: 1699659
[TBL] [Abstract][Full Text] [Related]
2. Sequence-dependent interaction of 5-fluorouracil and arabinosyl-5-azacytosine or 1-beta-D-arabinofuranosylcytosine.
Grem JL; Allegra CJ
Biochem Pharmacol; 1991 Jul; 42(2):409-18. PubMed ID: 1713459
[TBL] [Abstract][Full Text] [Related]
3. Bromodeoxyuridine enhancement of 1-beta-D-arabinofuranosylcytosine metabolic activation and toxicity in HL-60 leukemic cells.
Ross DD; Joneckis CC; Song TH; Wu RK
Cancer Res; 1988 Feb; 48(3):517-21. PubMed ID: 3335018
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and RNA incorporation of cyclopentenyl cytosine in human colorectal cancer cells.
Yee LK; Allegra CJ; Trepel JB; Grem JL
Biochem Pharmacol; 1992 Apr; 43(7):1587-99. PubMed ID: 1567480
[TBL] [Abstract][Full Text] [Related]
5. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
Danhauser LL; Rustum YM
Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside.
Tanaka M; Kimura K; Yoshida S
Jpn J Cancer Res; 1985 Aug; 76(8):729-35. PubMed ID: 3930450
[TBL] [Abstract][Full Text] [Related]
7. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
Riva CM; Rustum YM
Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
Grant S; Bhalla K; Rauscher F; Cadman E
Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
[TBL] [Abstract][Full Text] [Related]
9. Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells.
White JC; Hines LH
Cancer Res; 1987 Apr; 47(7):1820-4. PubMed ID: 3028615
[TBL] [Abstract][Full Text] [Related]
10. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
11. Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance.
Ahluwalia GS; Cohen MB; Kang GJ; Arnold ST; McMahon JB; Dalal M; Wilson YA; Cooney DA; Balzarini J; Johns DG
Cancer Res; 1986 Sep; 46(9):4479-85. PubMed ID: 2425954
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux.
Chan TC
Cancer Res; 1989 May; 49(10):2656-60. PubMed ID: 2713849
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA of human T-lymphoblastic cells (Molt-4).
Townsend A; Leclerc JM; Dutschman G; Cooney D; Cheng YC
Cancer Res; 1985 Aug; 45(8):3522-8. PubMed ID: 2410096
[TBL] [Abstract][Full Text] [Related]
15. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
16. Schedule-dependent enhancement of 1-beta-D-arabinofuranosylcytosine incorporation into HL-60 DNA by deoxyguanosine.
Ross DD; Akman SA; Joneckis CC; Yang E; Bachur NR
Cancer Res; 1984 Apr; 44(4):1530-5. PubMed ID: 6584206
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of cytotoxicity of 1-beta-D-arabinofuranosylcytosine for K562 human leukemic cells by cadeguomycin.
Suzuki H; Kim SH; Tanara M; Okazaki K; Okabe T; Wu RT; Tanaka N
Cancer Res; 1987 Feb; 47(3):713-7. PubMed ID: 3467840
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of N4-behenoyl-1-beta-D-arabinofuranosylcytosine through gradual conversion to 1-beta-D-arabinofuranosylcytosine in HeLa cells.
Maehara Y; Kusumoto T; Sakaguchi Y; Kusumoto H; Anai H; Sugimachi K
Anticancer Res; 1989; 9(1):41-4. PubMed ID: 2705754
[TBL] [Abstract][Full Text] [Related]
19. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67).
Grant S; Freemerman AJ; Birrer MJ; Martin HA; Turner AJ; Szabo E; Chelliah J; Jarvis WD
Cell Growth Differ; 1996 May; 7(5):603-13. PubMed ID: 8732670
[TBL] [Abstract][Full Text] [Related]
20. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
Kong XB; Tong WP; Chou TC
Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
